Investigating the Impact of Mode of Administration on Item Response
NCT ID: NCT00783991
Last Updated: 2013-06-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
800 participants
OBSERVATIONAL
2009-04-30
2009-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study is designed to examine how differences in modes of data capture affect psychometric properties and score differences and to evaluate the consistency of these results across three PROMIS health domains: emotional distress-depression, fatigue, and physical function. Four modes of administration will be compared: interactive voice response (IVR) technology, paper and pencil questionnaire, personal computer, and personal digital assistant (PDA). A total of 800 patients will be enrolled from three diagnostic groups: chronic obstructive pulmonary disease (COPD), depression, and rheumatoid arthritis. The study will test for equivalence across modes of administration, with the hypothesis that there are no mode effects; if mode effects are found, their magnitude across modes will be estimated. This network project will result in an improved understanding of the effect of assessment mode on patient-reported outcome (PRO) data. Guidance from this project can help in planning future PROMIS activities beyond the present PROMIS program.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Partnership in Resilience for Medication Safety (PROMIS)
NCT05880368
Proactive Reduction of Outpatient Malpractice: Increasing Safety, Efficiency, and Satisfaction
NCT01758315
Medication-taking Preferences & Practices of Patients With Chronic Conditions
NCT01614353
Testing the Impact of Pre-visit Priming for Medications
NCT07281131
Implementing a Pharmacist-Integrated Collaborative Model of Medication Treatment for Opioid Use Disorder
NCT05310786
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IVR-PC
This group will have instruments administered through interactive voice response (IVR) and personal computer (PC).
No interventions assigned to this group
PP-PC
This group will have instruments administered through paper and pencil (PP) and PC.
No interventions assigned to this group
PDA-PC
This group will have instruments administered by personal digital assistant (PDA) and PC.
No interventions assigned to this group
PC-PC
This group will have all instruments administered through PC.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Respondents required to take one or more of the following medications for their treatment:
1. COPD: Inhalative steroids (e.g., budesonide, beclometasone), oral medication with theophylline (dimethylxanthine), 2 mimetic (e.g., formoterol, salmeterol), leukotriene antagonists (e.g., montelukast), or oral corticosteroids (e.g., prednisolone)
2. DEP: Anti-depressive drugs (e.g., mirtazapine, escitalopram) and/or received a recognized psychotherapeutic treatment for depression within the last year
3. RA: Anti-inflammatory medications (e.g., Cox-2 inhibitors, acetylsalicylic acid of more than 500mg/d, diclofenac, ibuprofen), immunosuppressants (e.g., methotrexate, leflunomide), immune modulators (e.g., infliximab, etanercept), or steroids (e.g., prednisolone) for current treatment of RA
* Fluent in English
* Have Internet access and an e-mail address (for the IVR-PC, PP-PC and PC-PC arms)
* Willing and able to give informed consent
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
QualityMetrics
INDUSTRY
Endeavor Health
OTHER
Stanford University
OTHER
Stony Brook University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John E. Ware, PhD
Role: PRINCIPAL_INVESTIGATOR
QualityMetrics
Arthur Stone, PhD
Role: PRINCIPAL_INVESTIGATOR
Stony Brook University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Polimetrix
Palo Alto, California, United States
Rheumatology Associates of Long Island
Smithtown, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-05
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.